CRVS Earnings Corvus Pharmaceuticals, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated
Annual results
EPS
Net income
ROE
Quarterly results
EPS
Net income
ROE
Reported EPS history
1–27 of 27
| Q2 2026 | 2026-06-30 | -0.35 | 2026-08-06 | 10-Q |
| Q1 2026 | 2026-03-31 | -0.15 | 2026-05-07 | 10-Q |
| FY 2025 | 2025-12-31 | -0.53 | 2026-03-12 | 10-K |
| Q3 2025 | 2025-09-30 | -0.38 | 2025-11-04 | 10-Q |
| Q2 2026 | 2025-06-30 | -0.26 | 2026-08-06 | 10-Q |
| Q1 2026 | 2025-03-31 | -0.13 | 2026-05-07 | 10-Q |
| FY 2025 | 2024-12-31 | -1.02 | 2026-03-12 | 10-K |
| Q3 2025 | 2024-09-30 | -0.86 | 2025-11-04 | 10-Q |
| Q2 2025 | 2024-06-30 | -0.18 | 2025-08-07 | 10-Q |
| Q1 2025 | 2024-03-31 | -0.12 | 2025-05-08 | 10-Q |
| FY 2025 | 2023-12-31 | -0.56 | 2026-03-12 | 10-K |
| Q3 2024 | 2023-09-30 | -0.43 | 2024-11-12 | 10-Q |
| Q2 2024 | 2023-06-30 | -0.31 | 2024-08-06 | 10-Q |
| Q1 2024 | 2023-03-31 | -0.17 | 2024-05-07 | 10-Q |
| FY 2024 | 2022-12-31 | -0.89 | 2025-03-25 | 10-K |
| Q3 2023 | 2022-09-30 | -0.68 | 2023-11-07 | 10-Q |
| Q2 2023 | 2022-06-30 | -0.36 | 2023-08-08 | 10-Q |
| Q1 2023 | 2022-03-31 | -0.18 | 2023-05-08 | 10-Q |
| FY 2023 | 2021-12-31 | -1.03 | 2024-03-19 | 10-K |
| Q3 2022 | 2021-09-30 | -0.84 | 2022-11-03 | 10-Q |
| Q2 2022 | 2021-06-30 | -0.61 | 2022-08-08 | 10-Q |
| Q1 2022 | 2021-03-31 | -0.34 | 2022-05-05 | 10-Q |
| FY 2021 | 2020-12-31 | -0.20 | 2023-03-28 | 10-K |
| FY 2021 | 2019-12-31 | -1.59 | 2022-03-10 | 10-K |
| FY 2021 | 2019-09-30 | -0.33 | 2022-03-10 | 10-K |
| FY 2021 | 2019-06-30 | -0.36 | 2022-03-10 | 10-K |
| FY 2021 | 2019-03-31 | -0.44 | 2022-03-10 | 10-K |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.